Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic …
JB Kuemmerle-Deschner, E Hachulla… - Annals of the rheumatic …, 2011 - Elsevier
Objective Longer-term effects of prolonged selective interleukin-1β blockade with
canakinumab were evaluated in the largest cohort of cryopyrin-associated periodic
syndrome (CAPS) patients studied to date. Methods Adult and paediatric CAPS patients (n=
166, including canakinumab-naive and pretreated patients from previous studies) received
canakinumab subcutaneously 150 mg or 2 mg/kg (≤ 40 kg) every 8 weeks for up to 2 years.
Response and relapse was assessed using scores for disease activity, skin rash and C …
canakinumab were evaluated in the largest cohort of cryopyrin-associated periodic
syndrome (CAPS) patients studied to date. Methods Adult and paediatric CAPS patients (n=
166, including canakinumab-naive and pretreated patients from previous studies) received
canakinumab subcutaneously 150 mg or 2 mg/kg (≤ 40 kg) every 8 weeks for up to 2 years.
Response and relapse was assessed using scores for disease activity, skin rash and C …